PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors

mTOR coordinates protein synthesis, mitochondrial activity and proliferation

(2015) Masahiro Morita et al.   CELL CYCLE

Molecular landscape of pancreatic cancer: implications for current clinical trials

(2015) Gregory M. Heestand et al.   Oncotarget

Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies

(2015) Andrea Teague et al.   Therapeutic Advances in Medical Oncology

PI3K Regulation of RAC1 Is Required for KRAS-Induced Pancreatic Tumorigenesis in Mice

(2014) Chia-Yen C. Wu et al.   GASTROENTEROLOGY

Rapid Induction of Apoptosis by PI3K Inhibitors Is Dependent upon Their Transient Inhibition of RAS-ERK Signaling

(2014) M. Will et al.   Cancer Discovery

Selective Requirement of PI3K/PDK1 Signaling for Kras Oncogene-Driven Pancreatic Cell Plasticity and Cancer

(2013) Stefan Eser et al.   CANCER CELL

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

(2013) Violeta Serra et al.   JOURNAL OF CLINICAL INVESTIGATION

Recent Developments of Small Molecule PI3K/mTOR Dual Inhibitors

(2013) Yan-Na Liu et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Development of PI3K inhibitors: lessons learned from early clinical trials

(2013) Jordi Rodon et al.   Nature Reviews Clinical Oncology

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

(2013) H. Ebi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Mice Expressing Activated PI3K Rapidly Develop Advanced Colon Cancer

(2012) A. A. Leystra et al.   CANCER RESEARCH

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

(2012) F. Janku et al.   CANCER RESEARCH

Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing

(2012) C. A. Iacobuzio-Donahue et al.   CLINICAL CANCER RESEARCH

Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation

(2011) J. R. Adams et al.   CANCER RESEARCH

Pancreatic ductal cells in development, regeneration, and neoplasia

(2011) Maximilian Reichert et al.   JOURNAL OF CLINICAL INVESTIGATION

High-Throughput Mutation Profiling in Intraductal Papillary Mucinous Neoplasm (IPMN)

(2011) Nir Lubezky et al.   JOURNAL OF GASTROINTESTINAL SURGERY

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

(2011) F. Janku et al.   MOLECULAR CANCER THERAPEUTICS

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapamycin Inhibits Anal Carcinogenesis in Two Preclinical Animal Models

(2010) M. K. Stelzer et al.   Cancer Prevention Research

Hot-spot mutations in p110α of phosphatidylinositol 3-kinase (PI3K): Differential interactions with the regulatory subunit p85 and with RAS

(2010) Li Zhao et al.   CELL CYCLE

Image-Quality Assessment for Several Positron Emitters Using the NEMA NU 4-2008 Standards in the Siemens Inveon Small-Animal PET Scanner

(2010) J. A. Disselhorst et al.   JOURNAL OF NUCLEAR MEDICINE

Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape

(2010) S. K. Pal et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras

(2009) Sharon Y. Gidekel Friedlander et al.   CANCER CELL

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

(2009) Lakshmi Srinivasan et al.   CELL

PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas

(2008) Frank Schönleben et al.   LANGENBECKS ARCHIVES OF SURGERY

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS